Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like CTSO breaking down pretty hard. Those sales aren't helping the stock price much at the moment.
Meanwhile, our little "study and trials" company is holding it's own pretty well for now.
I can see the NFL going from trying to squelch this issue to realizing that they had better throw all of their resources behind finding a good way of diagnosing/curing this condition.
I understand their market cap is higher, but for all their sales and approvals, the stock price is today where it was 2 years ago.
CTSO stock price is at same level it was two years ago. So what are they doing so wrong with their sales and approvals?
Agreed, and a stellar balance sheet for a company at this stage of development. JJ has done a great job in this regard, at the very least.
What did you think of the conference call Hopester?
How's CTSO doing?
Definitely getting new exposure/publicity when the CTE papers are published "within the next 60 days"...timing should be good around NFL playoff time...
..we at least got some explanations for the Hep-C delays...DARPA project coming to its conclusion in September...other new stuff...sounds promising as always...
Hopester, feel free to promote your CTSO investment elsewhere
Sounds about right re this guy DJ, he's a dope all the way
All I can say, in reading between the lines of silence, is there MUST be some good things brewing that the market doesn't know about.
Exactly, that is Aethlon's filter in the Wyss video that was on yahoo a few weeks ago.
Ameritrade customers, still waiting for spinoff shares?
Definitely would be a great time to have some positive news out in regards to the CTE study with Boston U.
Yessir, that's what I've been thinking too.
Thanks, still good stuff
Wow, coming up on 15 million shares traded, shades of the ebola days last fall.
We know it's safe and we know it removes viruses. Both of those facts will be officially confirmed in the safety study.
Two days in a row, huge volume in the last hour, priced pushed over $10, what's up?
100k traded, most near close?
True but CTSO had some disappointing fundamental news during that time period that contributed to that--lost all its momentum fundamentally. Time will tell with us.
Let's hope he's got some news soon to capitalize on the new trading platform. A little surprised the financing was done before this though....I supposed to induce a multi-million investment the price had to be right.
Hopester always appreciate your technical analysis...is there a reason for the caps? You must be aware this implies you are shouting at the board.
thanks Bill
Hopester, always appreciate your insight in to charts and technicals, but some of your statements on the fundamental side are stated with such certainty--but you are just guessing...will additional stock be issued? Maybe.
There are other possibilities you may not be aware of...strategic investments are not out of the question and would also account for why the s-1 was withdrawn...
I understand your strategy--you don't mind missing a few precentage points at the start of a reversal to avoid sitting on dead money for who knows how long, and I can't argue with that. I think that is sound.
No I'm thinking it is something good they don't want to allow a competitor to see
interesting
Best to you dj, thanks for your input here (I've been around since 2003 in varying capacity, went in big in 2010 just before the DOD contract, got out of half last November, and back in heavy again in the high teens before the split).
They actually lowered price target from .74 to .52 but who's counting, I'd take either lol
The wild card event that nobody is considering now may lie in their Exosome Sciences subsidiary.
I understand. Only way to trade if you don't want to sit and wait without ammo.
Nasty stuff
Dual holders of AEMD and CTSO selling AEMD to buy more CTSO now (imo)
Fair enough. I just can't believe he literally does not want to commercialize as soon as possible...I had breakfast with him a couple of years ago. I believe in him, and just my opinion.
I agree the recent moves have raised questions--I just have faith they will be answered in time in a pleasing way.
Hopester, have you ever met or even talked to Joyce? You seem to have a great insight in to his plans and strategy.
Aethlon Medical Announces Health Canada Approval of Ebola Treatment Protocol
SAN DIEGO, May 13, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today disclosed that the Medical Devices Bureau of Health Canada has approved a clinical study protocol to treat Ebola-infected individuals with the Aethlon Hemopurifier®. The Hemopurifier is a first-in-class affinity biofiltration device designed for the broad-spectrum elimination of viral pathogens from the circulatory system of infected individuals. The device targets antiviral drug resistance and serves as a first-line countermeasure against Ebola and other life-threatening viruses that are not addressed with proven drug therapies. Health Canada is the Federal department responsible for overseeing the health of Canadian citizens.
View photo
.Aethlon Hemopurifier.
The Health Canada approved protocol is entitled, "The Treatment of Ebola Virus Disease (EVD) in Humans with the Aethlon Hemopurifier Lectin Affinity Plasmapheresis Device". The protocol allows for an investigational study of Hemopurifier therapy to be conducted in up to 3 human subjects. The objective of the study is to standardize and evaluate the use of the Hemopurifier as supportive care in the treatment of EVD. There is no assurance that the investigational study will result in the collection of clinical data that would support Health Canada licensing requirements. Aethlon further disclosed that the Ebola study protocol had also been approved by the University Health Network
Right, it's a mystery...hopefully we get an answer soon that solves it pleasantly.
I agree about the r/s and the lack of expected good news associated with it to support it...the only thing I can take from it is he wanted to squash the trading volatility, for which he has been successful. Not a trading stock anymore with that bid/ask spread. Not attractive to institutions either.
Can't argue with your strategy.
Other than what may surprise you.
No mention of Aethlon, but Thomas Jefferson is who we inked a research deal with recently
http://apnews.myway.com/article/2015...32a5c5c33.html
New blood tests, liquid biopsies, may transform cancer care
May 11, 3:07 AM (ET)
By MARILYNN MARCHIONE
(AP) Patient Carole Linderman speaks to Dr. Massimo Cristofanilli before her blood is...
Full Image
A new type of blood test is starting to transform cancer treatment, sparing some patients the surgical and needle biopsies long needed to guide their care.
The tests, called liquid biopsies, capture cancer cells or DNA that tumors shed into the blood, instead of taking tissue from the tumor itself. A lot is still unknown about the value of these tests, but many doctors think they are a big advance that could make personalized medicine possible for far more people.
They give the first noninvasive way to repeatedly sample a cancer so doctors can profile its genes, target drugs to mutations, tell quickly whether treatment is working, and adjust it as the cancer evolves.
Two years ago, these tests were rarely used except in research. Now, several are sold, more than a dozen are in development, and some doctors are using them in routine care.
(AP) Patient Carole Linderman has her blood drawn for a liquid biopsy at Jefferson...
Full Image
Gurpaul Bedi had one for colon cancer that spread to his lungs. About 10 percent of patients with metastatic colon cancer at the University of Texas MD Anderson Cancer Center now get liquid biopsies.
"I think it's wonderful," said Bedi, who lives in Atlanta and goes to Houston for his care. "A lung biopsy, many doctors told me, is not easy."
In Philadelphia, a liquid biopsy detected Carole Linderman's breast cancer recurrence months before it normally would have been found.
"Had this test not been available, we may not have known I had cancer on my spine until symptoms showed up," which may have been too late for good treatment, she said.
The huge potential for these tests is clear. The problem: There are no big, definitive studies to show they help patients, how accurate they are, which type is best or who should get them and when.
(AP) Dr. Massimo Cristofanilli, oncologist and director of the Breast Care Center, speaks...
Full Image
Still, patients do better when drugs are matched to their tumors, and liquid biopsies may give a practical way to do that more often.
"I'm really excited about all of this," said Dr. Razelle Kurzrock, a University of California, San Diego cancer specialist. "I spent most of my life giving drugs that were useless to people" because there was no good way to tell who would benefit or quickly tell when one wasn't working, she said. "This is so much better."
WHO GETS TESTED NOW
The tests are mostly used when a tissue biopsy can't easily be done, when the cancer's original site isn't known, or when drugs have stopped working and doctors are unsure what to try next, said Dr. Scott Kopetz, a colon cancer specialist at MD Anderson. The tests are catching on "faster than I anticipated," he said.
At Philadelphia's Thomas Jefferson University, Dr. Massimo Cristofanilli has used them on about 120 breast cancer patients, including two dozen like Linderman with a high risk of recurrence.
(AP) Patient Carole Linderman has her blood drawn for a liquid biopsy, during an...
Full Image
A tissue biopsy typically samples one section of a tumor, and tumors can vary widely, with different genes and hormones active in different parts, he said. Also, cancer that has spread often differs from the original site, and tumors change rapidly in response to treatment.
With a tissue biopsy, "our treatments lag behind and they're still based on limited information," Cristofanilli said. With a liquid biopsy, "the power of this test has been to really find out how the disease changes, even in a short period of time."
HOW THEY WORK
Early versions looked for whole tumor cells in blood. Newer ones look for free-floating cancer DNA, enabling gene profiling to see what mutations drive the cancer. Kopetz and Cristofanilli use one from Guardant Health Inc. of Redwood City, California, that has been sold in the U.S. since June 2014 and in parts of Europe and Asia.
Many companies are working on similar tests including Sequenom, a San Diego biotech that already sells one for prenatal screening, using fetal DNA in maternal blood. Many companies tried prenatal screening with fetal cells but it didn't work, said chief science officer Dirk van den Boom. "Cell-free DNA really was the breakthrough" that enabled wide use, and the same could happen with these cancer tests, he said.
(AP) Patient Carole Linderman has her blood drawn for a liquid biopsy, during an...
Full Image
THE COST
Whether liquid biopsies will be cost-effective is unknown. Guardant's test costs $5,400; some insurers cover it for certain types of patients. Gene profiling from a tissue biopsy costs about the same. The promise of liquid biopsies is that they can be done periodically to monitor care, but more tests means more cost.
They may save other costs, though. A traditional lung biopsy is thousands of dollars. Money could be saved by skipping cancer drugs that ultimately don't work; many cost $10,000 to $15,000 a month.
With cell-free DNA tests, even doctors in rural areas can offer precision medicine because they can ship a blood sample to a lab. "We think that's the future," said Dr. Charles Baum, a former Pfizer cancer drug chief who now heads Mirati Therapeutics, a San Diego biotech company developing gene-targeting drugs
DO THEY WORK?
(AP) Patient Carole Linderman hugs Dr. Massimo Cristofanilli before her blood is drawn...
Full Image
Many studies suggest that liquid biopsy results largely mirror those from tissue ones, and sometimes find more mutations. A study Kopetz presented in April at an American Association for Cancer Research meeting found the blood tests detected cancer mutations in the vast majority of 105 colorectal cancer patients. For 37 percent of them, doctors thought a drug could target a mutation that was found.
Still, no big studies show that liquid biopsies give better care or extend lives. Without that proof, how much they will be used by doctors and covered by insurers remains to be seen.
THE FUTURE
A San Diego company, Trovagene, is working on an even faster, easier liquid biopsy — a test to detect tumor DNA in urine. One scenario: a patient collects a urine sample every day for a week after starting a new drug and ships them to a lab.
"In as little as three to five days, you can observe dramatic changes" that suggest a response to treatment, said Trovagene's chief executive, Antonius Schuh.
Work on this test is still very early.
Ultimately, liquid biopsies might offer a way to screen for cancer besides the mammograms, colonoscopies and other methods used now. That raises even more questions, including when to call something "cancer" and whether it needs treatment if there are only abnormal cells in the blood.
"Why does there have to be a tumor? The tumor is the symptom. The disease is the DNA," Schuh said